Ignite Creation Date:
2024-05-06 @ 6:56 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05838326
Status:
COMPLETED
Last Update Posted:
2023-12-27
First Post:
2023-04-05
Brief Title:
Optiflow Duet Interface vs Standard High Flow Nasal Cannula
Sponsor:
University of Padova
Organization:
University of Padova
Study Overview
Official Title:
Physiological Effects of High Flow Oxygen Therapy Using Optiflow Duet Interface vs Standard High Flow Nasal Cannula for Acute Respiratory Failure After Extubation The OPTIMARF Study
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMARF
Brief Summary:
High-flow nasal cannula HFNC therapy is increasingly used in the management of acute respiratory failure Its clinical application has been largely investigated in chronic obstructive pulmonary disease COPD patients but only marginally in patients experiencing acute respiratory failure after extubation Promising data have been published in vitro about new asymmetrical high flow nasal cannula named Optiflow DUET Positive airway pressure that dynamically changes with breathing and clearance of anatomical dead space are the key mechanisms of noninvasive respiratory support with nasal high flow Pressure mainly depends on flow rate and nare occlusion The hypothesis is that an increase in asymmetrical occlusion of the nares leads to an improvement in dead-space clearance resulting in a reduction in re-breathing and breathing work
Detailed Description:
A prospective cross-over RCT on the effects of Optiflow DUET as compared to convetional symmetrical high flow cannula and Venturi mask
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None